Helena M Andersson
Overview
Explore the profile of Helena M Andersson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
153
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reglinska-Matveyev N, Andersson H, Rezende S, Dahlback B, Crawley J, Lane D, et al.
Blood
. 2014 Apr;
123(25):3979-87.
PMID: 24740810
Protein S is a cofactor for tissue factor pathway inhibitor (TFPI), accelerating the inhibition of activated factor X (FXa). TFPI Kunitz domain 3 residue Glu226 is essential for enhancement of...
2.
Ahnstrom J, Andersson H, Hockey V, Meng Y, McKinnon T, Hamuro T, et al.
Blood
. 2012 Oct;
120(25):5059-62.
PMID: 23074276
Protein S is a cofactor for tissue factor pathway inhibitor (TFPI) that critically reduces the inhibition constant for FXa to below the plasma concentration of TFPI. TFPI Kunitz domain 3...
3.
Andersson H, Siegerink B, Luken B, Crawley J, Algra A, Lane D, et al.
Blood
. 2011 Nov;
119(6):1555-60.
PMID: 22110247
VWF and ADAMTS13 are major determinants of platelet adhesion after vessel injury. In the present study, we aimed to determine whether VWF or ADAMTS13 plasma antigen levels influence the risks...
4.
Ahnstrom J, Andersson H, Canis K, Norstrom E, Yu Y, Dahlback B, et al.
Blood
. 2011 Apr;
117(24):6685-93.
PMID: 21508412
Protein S has an important anticoagulant function by acting as a cofactor for activated protein C (APC). We recently reported that the EGF1 domain residue Asp95 is critical for APC...
5.
Andersson H, Arantes M, Crawley J, Luken B, Tran S, Dahlback B, et al.
Blood
. 2010 Mar;
115(23):4878-85.
PMID: 20308596
Protein S has an established role in the protein C anticoagulant pathway, where it enhances the factor Va (FVa) and factor VIIIa (FVIIIa) inactivating property of activated protein C (APC)....